Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Researchers discovered that memory B cells produce non-specific antibodies to combat virus mutants, working alongside phagocytes to screen for variants. This mechanism may offer protection against SARS-CoV2 and HIV variants, and could influence vaccine development.
Researchers developed a new test method to detect tuberculosis (TB) progression from latent infection in elephants using IgG antibodies against Antigen 85B. High levels of IgG against ESAT6/CFP10 remained constant, while IgG against Ag85B increased before disease onset and declined with treatment.
Scripps Research scientists found that COVID-19 patients develop more robust antibodies against coronaviruses causing common colds and SARS-CoV-1 and MERS-CoV. This increased antibody response may lead to improved vaccine development, targeting a broader range of viruses.
A recent study presented at the 2022 ARRS Annual Meeting found that COVID-19 infection significantly impacted lung cancer screening in diverse inner-city populations. The research revealed that approximately 9% of participants developed COVID-19 during the pandemic, with mortality rates reaching 6.9%.
Researchers at the Medical University of South Carolina have developed a highly accurate and minimally invasive test for detecting liver fibrosis. The test, GlycoFibroTyper, measures changes in sugar molecules attached to antibodies in patient blood samples.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Research found that 3.4% of pregnant women who caught COVID-19 passed antibodies to their babies, providing some protection. However, these antibodies gradually decrease over time and disappear within 100 days after birth.
A new study from the University of Illinois at Urbana-Champaign has developed a machine-learning model that can predict which pathogens antibodies will target, with an accuracy rate of over 85%. The model uses genetic sequences of antibodies to differentiate between influenza and SARS-CoV-2.
Researchers at Gwangju Institute of Science and Technology (GIST) have developed a new technique to easily visualize viruses using an optical microscope, called the Gires-Tournois immunoassay platform. The platform uses 'slow light' technology to detect coronavirus particles by slowing down light that gets reflected around them.
Researchers at Karolinska Institutet study how the immune system protects against malaria, finding that people who have contracted the disease before develop a tolerance that prevents severe disease. This knowledge can aid in the development of more effective vaccines.
Researchers have developed a new treatment for chronic inflammation by targeting the ASC protein with nanobodies, which can dissolve harmful molecular complexes and counteract inflammation. The treatment has shown promising results in mouse models, alleviating symptoms of rheumatoid arthritis and gout.
Researchers at Charité, MDC, and FU Berlin have studied the mechanisms of action of antibody and dexamethasone treatments for COVID-19. They found that combination therapy is more effective in reducing viral activity and inflammation in lung tissue, suggesting a potential game-changer in treating severe cases.
A recent study found that the Omicron variant is associated with a significant increase in breakthrough infections among cancer patients, especially those undergoing treatment. Protective measures and vaccine adaptations are crucial to mitigate this risk.
Researchers developed a new treatment option for relapsed or refractory CD30+ lymphoma using natural killer cells complexed with a CD30/CD16A bispecific antibody. The treatment showed an overall response rate of 89% in patients with advanced lymphoma.
A new biodegradable gel has been developed to improve the immune system's ability to combat cancer. The gel releases drugs and special antibodies that target tumor cells, slowing their growth and increasing the lifespan of mice. This breakthrough could lead to new clinical trials for human patients in the coming years.
A third dose of COVID-19 vaccine significantly increases immune responses in patients with multiple myeloma, but a subset remains vulnerable. The study found that 88% of patients developed antibodies after the third dose, leading to improved neutralization of the wild-type virus.
The newly developed COVID vaccine, PreS-RBD, targets the receptor binding domains of SARS-CoV-2 and induces a robust immune response. The vaccine has shown effectiveness in protecting against all known SARS-CoV-2 variants, including omicron, even in individuals who have not previously built up immunity.
Researchers found that prior infection with common human coronaviruses does not provide immunity against SARS-CoV-2 due to limited cross-reactive antibodies. This suggests no significant adverse effects from antibody-dependent enhancement, reducing the risk of COVID-19 complications.
Researchers found that older killifish have less diverse circulating antibodies compared to younger fish, contributing to reduced immune function. This decrease in antibody diversity may lead to a reduced ability to respond to infections.
Researchers at Karolinska Institutet in Sweden have developed a novel strategy to identify potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that effectively blocked infection with different SARS-CoV-2 variants.
Researchers at Kobe University discover that immobilization induces loss of muscle mass by disrupting calcium levels and triggering the KLF15-IL-6 pathway. This finding may lead to the development of a treatment for muscle loss, known as sarcopenia, which affects aging societies.
A University of Gothenburg study found that IgA antibodies present in the respiratory tract protected healthcare workers from contracting COVID-19. The research, published in the European Journal of Immunology, suggests that these antibodies may play a crucial role in preventing severe illness and hospitalization.
A team of Canadian scientists developed a scalable serology assay to track COVID-19 antibodies, informing public health decisions and vaccine timing. The assay has been used in over 30 studies across Canada, capturing natural infection and vaccination responses with high accuracy.
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
Researchers at Max Planck Institute of Molecular Physiology discovered that vaccination after COVID-19 recovery increases neutralizing antibody levels by up to five times, providing better protection against current coronavirus variants. The study involved 140 volunteers and showed that antibody levels remained high even after 300 days.
Children previously infected with COVID-19 develop long-lasting natural circulating antibodies that provide immunity. The study's findings suggest that these antibodies can last for at least seven months and do not differ by age, weight, or severity of symptoms.
A new study found that follicular T cells help balance out antibody diversity and affinity after COVID-19 vaccination. Deleting specific cell types altered the immune response, providing insights into strategies to enhance vaccine effectiveness later in life.
A study compared the antibody response in human milk after vaccination with four COVID-19 vaccines, revealing differences in immune system activation. The findings provide valuable insights into vaccine effectiveness and potential impact on infant health.
A new Moffitt Cancer Center study estimates that the actual number of COVID-19 infections in Hillsborough County was twofold higher than reported positive tests. The study, conducted between October 2020 and March 2021, found nearly 100% of persons who had confirmed or suspected infection were antibody-positive.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
The new laboratory will use microfluidics, AI, and machine learning to conduct thousands of parallel experiments on single-cell eukaryotic yeast and other microbes. This will simplify the study of biology and provide a pathbreaking 'robot scientist' for fundamental research.
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
A new study by University of Bonn researchers found that cow's milk protein casein triggers an autoimmune response in mice, damaging neurons and myelin sheath. This cross-reactivity can occur when the immune system mistakes similar molecules for each other.
Researchers developed a mathematical model to predict how antibodies generated by COVID-19 vaccines confer protection against symptomatic infections. The study found that vaccine efficacy is linked to the level of neutralization titre and could enable testing of future vaccines before clinical trials.
Researchers have discovered that bioprosthetic heart valve patients develop an immune response against foreign sugars in the valves, leading to calcification and deterioration. By genetically engineering these sugars out of the valves, durability can be increased, offering a potential solution for patients.
A new study from Oregon Health & Science University found that people infected with SARS-CoV-2 develop durable immunity against variants for at least 11 months. The research suggests that immune protection may endure long-term, potentially reducing the need for vaccine booster shots.
Aston University researchers developed an AI model that can estimate daily Covid transmission rates using data from antibody tests in blood donors. The model provides a more refined view of infection rates and relative immunity compared to official measurements.
A study by MedUni Vienna found that dual-vaccinated and recovered individuals have virtually no protection against infection with the current Omicron variant of SARS-CoV-2. However, a third Corona vaccination provides partial blockade of Omicron.
A new transistor-based technology has been developed to quantify SARS-CoV-2 neutralizing antibodies in blood serum and test the efficacy of new vaccines. The device allows for fast and real-time analysis, reducing response times and costs.
Researchers have created a new type of cholera vaccine consisting of polysaccharides displayed on virus-like particles, generating long-lasting antibody responses in mice. The vaccine shows promise as a next-generation cholera vaccine, potentially replacing current vaccines that last only 2-5 years.
Researchers tracked antibody response to COVID-19 vaccination and found that antibodies improve in quality for months after vaccination. Even low levels of antibodies provide some protection as long as the virus doesn't change.
Researchers found that 90 minutes of mild-to-moderate intensity exercise after a flu or COVID-19 vaccination increased antibody production in the following four weeks. The study involved participants who exercised on a stationary bike or took a brisk walk, and similar results were seen in mice experiments.
A study found that previous COVID-19 infection improves the performance of antibodies and potentially provides longer-term protection, especially in obese individuals. In contrast, vaccination does not enhance antibody quality and may not provide sustained immunity in those who have been previously infected or overweight.
A new US-based study published in PLOS Biology found that most people who have had COVID-19 are protected against reinfection for at least six months. The research analyzed data from 4,441 SpaceX employees and estimated an odds ratio of 0.14 to 0.28 for reinfection depending on the time period considered.
A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Biologists isolated the SARS-CoV-2 nucleoprotein in its pure form to create more accurate antibody tests. The new approach significantly improves sensitivity, increasing the ability to detect antibodies to the nucleoprotein. This breakthrough helps determine if vaccinated individuals have been infected with COVID-19.
A recent study from Massachusetts General Hospital found that COVID-19 vaccination during pregnancy results in higher and more lasting antibody levels in infants. After two months, 98% of vaccinated infants had detectable IgG antibodies, while only 8% of uninfected mothers' babies did.
Children who receive repeated seasonal flu vaccines develop antibodies that provide broader protection against new strains, including pandemic viruses. This finding informs the design of a universal influenza virus vaccine for children.
Researchers developed a single-use sensor strip that can detect cerebrospinal fluid (CSF) leaks, providing a rapid diagnostic tool for patients with brain and spinal cord injuries. The test uses antibodies specific to proteins found in human CSF, detecting leaks even when other substances are present.
Researchers have characterized broadly neutralizing antibodies against the hepatitis C virus, identifying key genetic determinants of broad neutralization. These findings offer a promising basis for developing an effective vaccine against HCV.
Lab tests show current anti-COVID pills remain effective against omicron, but available antibody therapies are substantially less effective. Researchers tested various treatments and found that some antibodies have lost their ability to neutralize omicron at realistic dosages.
Patients under immunosuppressive therapy have increased risk of severe COVID-19 disease courses if they don't respond to primary vaccination. A recent study found that a third booster vaccination is safe and effective in these patients, who were initially unable to produce antibodies after vaccination.
A new study finds that breakthrough infections following vaccination and natural infection followed by vaccination provide roughly equal levels of enhanced immune protection. Researchers at OHSU found that both groups generated greater levels of immunity compared to those who were vaccinated with no infection.
A new study reveals the Beta variant of SARS-CoV-2 can elicit a wide range of antibodies effective against both Delta and Omicron variants. The findings suggest that vaccination strategies could be improved by leveraging this broad immunity.
Researchers at Kumamoto University developed a novel 'supermolecular' material that binds to protein drugs, prolongs their effect without impairing activity, and improves overall drug performance. The material, called PEG-PRX, adds polyethylene glycol chains to proteins without compromising biological action.
Researchers found a markedly increased risk of carditis associated with BNT162b2 vaccination, particularly in adolescents after the second dose. The study's findings highlight the need for refined vaccination strategies to balance risk and benefits across different sub-populations.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers at the University of Missouri identified 46 specific mutations in the Omicron variant that enable it to evade pre-existing antibodies. These mutations are particularly prevalent in the region where antibodies bind to the virus, making them a key target for future antiviral treatments.
A UK study found that over a third of care home residents and a quarter of staff in England showed evidence of SARS-CoV-2 infection during the first two waves of the pandemic. The study also revealed that antibodies against the virus became undetectable in half of the population within eight months.